Tumor mutational burden (TMB) is a promising biomarker for predicting positive patient response to immune checkpoint inhibitors.
TMB measurements can be determined using genomic DNA extracted from FFPE-preserved tissue biopsy samples. However, assessment of TMB from a surrogate blood sample (liquid biopsy) referred to as Blood TMB (bTMB), is an attractive alternative clinical diagnostic tool that would allow clinicians and patients to avoid the invasive challenge of tissue biopsies. Obtaining concordant bTMB results across assays has been challenging; thus, we have developed the new Seraseq Blood TMB reference materials at various mutational burden levels (7, 13, 20 & 26) from high-quality genomic DNA extracted from tumor-derived and their SNP-matched normal cell lines.
This poster from LGC Clinical Diagnostics demonstrates the use of the Seraseq Blood TMB Score reference materials to provide a tumor-normal matched blood TMB control to aid the development, validation, and quality control of cell-free DNA assays to determine blood tumor mutational burden scores of cancer patients.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences